Is Bluebird Bio stock a buy?

bluebird bio has received a consensus rating of Hold. The company’s average rating score is 2.18, and is based on 2 buy ratings, 13 hold ratings, and 1 sell rating.

Why is bluebird bio stock down?

The big drop came after the company announced that the Food and Drug Administration (FDA) placed its clinical testing of lovo-cel in treating sickle cell disease on partial clinical hold.

Is Bluebird undervalued?

Right now, Bluebird has over $1 billion in cash and investments with no debt, compared to a market cap of $2.1 billion. That leaves the company with an enterprise value of just $1.1 billion and undervalued even without accounting for the potential of LentiGlobin.

Is BLUE stock a buy?

During the day the stock fluctuated 3.75% from a day low at $6.67 to a day high of $6.92. The price has fallen in 6 of the last 10 days and is down by -5.94% for this period….Predicted Opening Price for bluebird bio of Monday, February 7, 2022.

Fair opening price February 7, 2022	Current price
$6.80	$6.81 (Overvalued)

Who bought bluebird bio?

Resilience has acquired bluebird’s North Carolina lentiviral vector manufacturing facility for $110 million. The 125,000-square-foot site in Durham, NC, includes drug substance and drug product production suites, quality control labs and warehouse space.

Who will acquire bluebird bio?

Just a little more than two years after bluebird bio purchased a manufacturing facility and spent another $80 million on upgrades, the company has spun around and sold it. Resilience has acquired bluebird’s North Carolina lentiviral vector manufacturing facility for $110 million.

What is Zynteglo used for?

Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. To make Zynteglo, the stem cells taken from the patient’s blood are modified by a virus that carries working copies of the beta-globin gene into the cells.

How much is Zynteglo?

After winning approval for the drug in Europe in June 2019, the company set a price of $1.8 million on the one-time treatment for beta-thalassemia. Manufacturing problems pushed the launch for Zynteglo back to January of this year.